APA (7th ed.) Citation

JA, B., SC, G., & SS, E. (2008). Adverse event detection in drug development: Recommendations and obligations beyond phase 3. American Journal of Public Health, 98(8), 1366. https://doi.org/10.2105/AJPH.2007.124537

Chicago Style (17th ed.) Citation

JA, Berlin, Glasser SC, and Ellenberg SS. "Adverse Event Detection in Drug Development: Recommendations and Obligations Beyond Phase 3." American Journal of Public Health 98, no. 8 (2008): 1366. https://doi.org/10.2105/AJPH.2007.124537.

MLA (9th ed.) Citation

JA, Berlin, et al. "Adverse Event Detection in Drug Development: Recommendations and Obligations Beyond Phase 3." American Journal of Public Health, vol. 98, no. 8, 2008, p. 1366, https://doi.org/10.2105/AJPH.2007.124537.